tiprankstipranks
CytomX Therapeutics Inc. (CTMX)
NASDAQ:CTMX
US Market
CTMX
CytomX Therapeutics
RESEARCH TOOLSreports
Want to see CTMX full AI Analyst Report?

CytomX Therapeutics (CTMX) Stock Forecast & Price Target

971 Followers
See the Price Targets and Ratings of:

CTMX Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
CytomX
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CTMX Stock 12 Month Forecast

Average Price Target

$12.30
▲(155.19% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for CytomX Therapeutics in the last 3 months. The average price target is $12.30 with a high forecast of $16.00 and a low forecast of $6.00. The average price target represents a 155.19% change from the last price of $4.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","5":"$5","9":"$9","13":"$13","17":"$17"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5,9,13,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.45,4.415384615384616,5.380769230769231,6.346153846153847,7.311538461538461,8.276923076923076,9.242307692307692,10.207692307692309,11.173076923076923,12.138461538461538,13.103846153846153,14.06923076923077,15.034615384615385,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.45,4.130769230769231,4.811538461538462,5.492307692307692,6.173076923076923,6.853846153846154,7.534615384615385,8.215384615384616,8.896153846153847,9.576923076923078,10.25769230769231,10.93846153846154,11.619230769230771,{"y":12.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.45,3.6461538461538465,3.8423076923076924,4.038461538461538,4.234615384615385,4.430769230769231,4.626923076923077,4.823076923076924,5.019230769230769,5.2153846153846155,5.411538461538462,5.607692307692307,5.803846153846154,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.34,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$16.00Average Price Target$12.30Lowest Price Target$6.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wolfe Research Analyst forecast on CTMX
Kalpit Patel
Wolfe Research
Wolfe Research
$6
Buy
24.48%
Upside
Initiated
05/19/26
CytomX Therapeutics initiated with an Outperform at Wolfe ResearchCytomX Therapeutics initiated with an Outperform at Wolfe Research
Oppenheimer Analyst forecast on CTMX
Matthew Biegler
Oppenheimer
Oppenheimer
$12
Buy
148.96%
Upside
Reiterated
05/13/26
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), CytomX Therapeutics (CTMX)
H.C. Wainwright Analyst forecast on CTMX
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$17→$11
Buy
128.22%
Upside
Reiterated
05/11/26
CytomX Therapeutics price target lowered to $11 from $17 at H.C. WainwrightCytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright
Barclays Analyst forecast on CTMX
Etzer Darout
Barclays
Barclays
$16
Buy
231.95%
Upside
Assigned
05/08/26
CytomX Therapeutics (CTMX) Gets a Buy from Barclays
Wedbush Analyst forecast on CTMX
Robert Driscoll
Wedbush
Wedbush
$11
Buy
128.22%
Upside
Reiterated
05/08/26
CytomX Therapeutics (CTMX) Gets a Buy from Wedbush
Piper Sandler Analyst forecast on CTMX
Edward Tenthoff
Piper Sandler
Piper Sandler
$12
Buy
148.96%
Upside
Reiterated
05/08/26
CytomX Therapeutics (CTMX) Receives a Buy from Piper Sandler
Guggenheim Analyst forecast on CTMX
Michael Schmidt
Guggenheim
Guggenheim
$15
Buy
211.20%
Upside
Reiterated
05/07/26
Guggenheim Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)
Cantor Fitzgerald Analyst forecast on CTMX
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$10→$12
Buy
148.96%
Upside
Reiterated
03/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on CTMX
Roger Song
Jefferies
Jefferies
$8→$16
Buy
231.95%
Upside
Reiterated
03/18/26
CytomX Therapeutics price target raised to $16 from $8 at JefferiesCytomX Therapeutics price target raised to $16 from $8 at Jefferies
J.P. Morgan Analyst forecast on CTMX
Anupam Rama
J.P. Morgan
J.P. Morgan
$7→$12
Buy
148.96%
Upside
Upgraded
03/16/26
CytomX Therapeutics upgraded to Overweight from Neutral at JPMorganCytomX Therapeutics upgraded to Overweight from Neutral at JPMorgan
Roth MKM Analyst forecast on CTMX
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$3.5
Buy
-27.39%
Downside
Initiated
09/17/25
CytomX Therapeutics (CTMX) Initiated with a Buy at Roth MKM
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wolfe Research Analyst forecast on CTMX
Kalpit Patel
Wolfe Research
Wolfe Research
$6
Buy
24.48%
Upside
Initiated
05/19/26
CytomX Therapeutics initiated with an Outperform at Wolfe ResearchCytomX Therapeutics initiated with an Outperform at Wolfe Research
Oppenheimer Analyst forecast on CTMX
Matthew Biegler
Oppenheimer
Oppenheimer
$12
Buy
148.96%
Upside
Reiterated
05/13/26
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), CytomX Therapeutics (CTMX)
H.C. Wainwright Analyst forecast on CTMX
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$17→$11
Buy
128.22%
Upside
Reiterated
05/11/26
CytomX Therapeutics price target lowered to $11 from $17 at H.C. WainwrightCytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright
Barclays Analyst forecast on CTMX
Etzer Darout
Barclays
Barclays
$16
Buy
231.95%
Upside
Assigned
05/08/26
CytomX Therapeutics (CTMX) Gets a Buy from Barclays
Wedbush Analyst forecast on CTMX
Robert Driscoll
Wedbush
Wedbush
$11
Buy
128.22%
Upside
Reiterated
05/08/26
CytomX Therapeutics (CTMX) Gets a Buy from Wedbush
Piper Sandler Analyst forecast on CTMX
Edward Tenthoff
Piper Sandler
Piper Sandler
$12
Buy
148.96%
Upside
Reiterated
05/08/26
CytomX Therapeutics (CTMX) Receives a Buy from Piper Sandler
Guggenheim Analyst forecast on CTMX
Michael Schmidt
Guggenheim
Guggenheim
$15
Buy
211.20%
Upside
Reiterated
05/07/26
Guggenheim Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)
Cantor Fitzgerald Analyst forecast on CTMX
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$10→$12
Buy
148.96%
Upside
Reiterated
03/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on CTMX
Roger Song
Jefferies
Jefferies
$8→$16
Buy
231.95%
Upside
Reiterated
03/18/26
CytomX Therapeutics price target raised to $16 from $8 at JefferiesCytomX Therapeutics price target raised to $16 from $8 at Jefferies
J.P. Morgan Analyst forecast on CTMX
Anupam Rama
J.P. Morgan
J.P. Morgan
$7→$12
Buy
148.96%
Upside
Upgraded
03/16/26
CytomX Therapeutics upgraded to Overweight from Neutral at JPMorganCytomX Therapeutics upgraded to Overweight from Neutral at JPMorgan
Roth MKM Analyst forecast on CTMX
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$3.5
Buy
-27.39%
Downside
Initiated
09/17/25
CytomX Therapeutics (CTMX) Initiated with a Buy at Roth MKM
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CytomX Therapeutics

3 Months
Etzer DaroutBarclays
Success Rate
8/14 ratings generated profit
57%
Average Return
+12.03%
Copying Etzer Darout's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +12.03% per trade.
1 Year
Robert DriscollWedbush
Success Rate
7/14 ratings generated profit
50%
Average Return
+21.21%
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +21.21% per trade.
2 Years
Edward TenthoffPiper Sandler
Success Rate
3/8 ratings generated profit
38%
Average Return
+67.84%
Copying Edward Tenthoff's trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of +67.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CTMX Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
10
19
15
21
10
Buy
1
1
0
0
0
Hold
1
1
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
21
16
21
10
In the current month, CTMX has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CTMX average Analyst price target in the past 3 months is 12.30.
Each month's total comprises the sum of three months' worth of ratings.

CTMX Financial Forecast

CTMX Earnings Forecast

Next quarter’s earnings estimate for CTMX is -$0.08 with a range of -$0.13 to $0.12. The previous quarter’s EPS was -$0.10. CTMX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CTMX has Performed in-line its overall industry.
Next quarter’s earnings estimate for CTMX is -$0.08 with a range of -$0.13 to $0.12. The previous quarter’s EPS was -$0.10. CTMX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CTMX has Performed in-line its overall industry.

CTMX Sales Forecast

Next quarter’s sales forecast for CTMX is $11.19M with a range of $0.00 to $50.00M. The previous quarter’s sales results were $10.26M. CTMX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CTMX has Performed in-line its overall industry.
Next quarter’s sales forecast for CTMX is $11.19M with a range of $0.00 to $50.00M. The previous quarter’s sales results were $10.26M. CTMX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CTMX has Performed in-line its overall industry.

CTMX Stock Forecast FAQ

What is CTMX’s average 12-month price target, according to analysts?
Based on analyst ratings, CytomX Therapeutics Inc.’s 12-month average price target is 12.30.
    What is CTMX’s upside potential, based on the analysts’ average price target?
    CytomX Therapeutics Inc. has 155.19% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CTMX a Buy, Sell or Hold?
          CytomX Therapeutics Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is CytomX Therapeutics Inc.’s price target?
            The average price target for CytomX Therapeutics Inc. is 12.30. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $16.00 ,the lowest forecast is $6.00. The average price target represents 155.19% Increase from the current price of $4.82.
              What do analysts say about CytomX Therapeutics Inc.?
              CytomX Therapeutics Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of CTMX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.